RAD21 and invasive ductal breast carcinoma: We assessed a real-world clinico-genomics cohort of 1164 breast invasive ductal carcinomas in which 20.6% (240) of patient tumors harbored a RAD21 alteration and 79.4% (924) were RAD21 WT.